The global circulating tumor cells (CTC) market size reached US$ 10.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 20.0 Billion by 2028, exhibiting a growth rate (CAGR) of 10.2% during 2023-2028.
Circulating tumor cells (CTC) are cancer cells that split away from the primary tumor and appear in the circulatory system as singular units or clusters. They have different biological phenotypes, such as epithelial, mesenchymal, and mixed epithelial-mesenchymal. CTC levels in a patient's blood can allow early detection of cancer and act as a prognostic indicator. As they are in minimal quantity, several technologies are used for the isolation, enrichment, and detection of CTC, such as immunocapture, size-based separation, density-based separation, and microscopy. It also has wide-ranging applications in liquid biopsy, cancer research, drug development, and clinical biomarkers.
Circulating Tumor Cells (CTC) Market Trends:
The increasing prevalence of cancer due to genetic disorders, rising alcohol consumption, and rapid lifestyle changes are key factors driving the market growth. CTC assists in the early identification and real-time monitoring of lung, breast, digestive tract, and prostate cancer. In line with this, the increasing utilization of CTC in patient screening for metastasis and preclinical studies of new cancer drugs is favoring the market growth. Furthermore, the growing demand for minimally invasive (MI) diagnostic procedures and widespread adoption of CTC-based liquid biopsy to enable rapid recovery and limit trauma are providing a considerable boost to the market growth. Apart from this, the introduction of nanotechnology to improve the sensitivity and efficiency of CTC isolation and detection is providing an impetus to market growth. Moreover, increasing utilization in medical research to develop cell culture models for drug screening, disease modeling, genome editing, and tumor immunity is creating a positive outlook for the market. Additionally, the increasing awareness amongst healthcare professionals and patients about the importance of early cancer diagnosis is positively influencing the market growth. Other factors, including rapid advancements in biomedical imaging and bioengineering technology, extensive research and development (R&D) activities, and the rising demand for preventive medicine and companion diagnostics, are anticipated to drive the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global circulating tumor cells (CTC)market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on technology, application, product, specimen and end user.
Breakup by Technology:
CTC Detection and Enrichment Method
CTC Direct Detection Methods
Breakup by Application:
Screening and Monitoring
Cancer Stem Cell and Tumorigenesis Research
Breakup by Product:
Kits and Reagents
Blood Collection Tubes
Devices and Systems
Breakup by Specimen:
Other Body Fluids
Breakup by End User:
Hospital and Clinics
Research and Academic Institutes
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being BioFluidica Inc, Creatv MicroTech Inc., CytoLumina Technologies Corp., Fluxion Biosciences Inc., Greiner Bio-One International GmbH, Ikonisys Inc, Menarini Silicon Biosystems, Miltenyi Biotec, Qiagen N.V, Rarecells Diagnostics and Stemcell Technologies.
Base Year of the Analysis
Technology, Application, Product, Specimen, End User, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global Circulating Tumor Cells (CTC) market was valued at US$ 10.7 Billion in 2022.
We expect the global Circulating Tumor Cells (CTC) market to exhibit a CAGR of 10.2% during 2023-2028.
The growing adoption of Circulating Tumor Cells (CTC) in liquid biopsy, cancer research, drug development, clinical biomarkers, etc., is primarily driving the global Circulating Tumor Cells (CTC) market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective cancer treatment procedures to reduce the risk of coronavirus infection upon hospital visits or interaction with medical equipment, thereby negatively impacting the global market for Circulating Tumor Cells (CTC).
Based on the technology, the global Circulating Tumor Cells (CTC) market has been segmented into CTC detection and enrichment method, CTC direct detection methods, and CTC analysis. Among these, CTC detection and enrichment method currently holds the majority of the global market share.
Based on the application, the global Circulating Tumor Cells (CTC) market can be divided into clinical/liquid biopsy and research. Currently, research accounts for the largest market share.
Based on the product, the global Circulating Tumor Cells (CTC) market has been segregated into kits and reagents, blood collection tubes, and devices and systems, where devices and systems currently exhibit a clear dominance in the market.
Based on the specimen, the global Circulating Tumor Cells (CTC) market can be bifurcated into blood, bone marrow, and other body fluids. Currently, blood holds the majority of the total market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global Circulating Tumor Cells (CTC) market include BioFluidica Inc, Creatv MicroTech Inc., CytoLumina Technologies Corp., Fluxion Biosciences Inc., Greiner Bio-One International GmbH, Ikonisys Inc, Menarini Silicon Biosystems, Miltenyi Biotec, Qiagen N.V, Rarecells Diagnostics, and Stemcell Technologies.
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.